 |
|
|
| |
Prevalence of Pre-Treatment NS5A Resistance Associated Variants in Genotype 1 Patients Across Different Regions Using Deep Sequencing and Effect on Treatment Outcome with LDV/SOF
|
| |
| |
Reported by Jules Levin
AASLD 2014 Nov 13-17 San Francisco
Stefan Zeuzem1, Masashi Mizokami2, Stephen Pianko3, Alessandra Mangia4, Kwang-Hyub Han5, Ross Martin6, Evguenia Svarovskaia6, Hadas Dvory-Sobol6, Brian Doehle6, Chohee Yun6, Diana M. Brainard6, Steven Knox6, John G. McHutchison6, Michael D. Miller7, Hongmei Mo6, Wan-Long Chuang8, Ira Jacobson9, Gregory Dore10, Mark Sulkowski11
1Goethe-Universität, Frankfurt am Main, Germany; 2National Center for Global Health and Medicine, Chiba, Japan; 3Monash Health and Monash University, Melbourne, Australia; 4IRCCS Hospital 'Casa Sollievo della Sofferenza', San Giovanni Rotondo, Italy; 5Yonsei University College of Medicine, Seoul, Korea; 6Gilead Sciences, Inc., Foster City, California, United States; 7University of Dundee, Dundee, United Kingdom; 8Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; 9Icahn School of Medicine at Mount Sinai, New York, New York, United States; 10The Kirby Institute, Sydney, Australia; 11Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
|
| |
|
|
|
|
|
